NATHBIOGENES Diversified 15 May 2026

Nath Bio-Genes Ltd — Q4 FY26

Q: What was Nath Bio-Genes's revenue in Q4 FY26?

Nath Bio-Genes reported revenue of ₹432 Cr in Q4 FY26, a +19% change year-over-year.

Nath Bio-Genes delivered a strong FY26 with revenue of ₹431.6 crore, up 19% YoY, driven by robust volume growth across cotton (+22%), paddy (+25%), and maize (+54%).

bullish high

Revenue ₹432 Cr +19%

EBITDA ₹53 Cr

PAT ₹38 Cr -8%

EBITDA Margin 12%

Duration 50 min

Read Time 1 min read

Financial stats pending filing verification

2-Minute Summary

✦ AI-Generated from Full Transcript

Nath Bio-Genes delivered a strong FY26 with revenue of ₹431.6 crore, up 19% YoY, driven by robust volume growth across cotton (+22%), paddy (+25%), and maize (+54%). EBITDA margin stood at 12%, while PAT declined 8% to ₹38.4 crore due to higher finance costs and tax rate normalization. The company highlighted production stability for flagship cotton hybrids Sankit and Jumbo, and a landmark ₹15 crore contribution from the Uzbekistan JV. Management guided for 15-20% revenue growth in FY27 with stable margins, despite potential El Niño risks. Key risks include inventory buildup (₹113 crore) and gross margin normalization from 63% to 56%.

Key Numbers

Cotton BT volume growth 13.88 lakh packets

+22.35% YoY

Driven by strong demand for flagship hybrids Sankit and Jumbo; production stability expected over next 2-3 years.

Maize volume growth 9,639 quintals

+54% YoY

Star performer; now contributes 10.72% to top line, driven by poultry and ethanol demand.

Cotton-paddy revenue mix 58%

+6pp YoY

Up from 52% in FY25, reflecting deepening penetration in core crops.

Uzbekistan JV revenue ₹15 crore

First-time contribution

Landmark milestone; JV targets Central Asian market worth $450M, with conservative 10-15% revenue share in 3-5 years.

Management Guidance

FY27 revenue growth of 15-20%

Management expects top line to grow 15-20% in FY27, driven by continued momentum in cotton, paddy, and maize.

Management guidance revenue

EBITDA and PAT margins to trend slightly upward

Management guided for EBITDA and PAT margins to maintain a slightly upward trend, with PAT margin expected to improve by 1-1.5% over FY26 levels.

Management guidance margins

Minimal capex; focus on rental infrastructure

No major capex planned for processing or storage; company prefers renting to avoid underutilization.

Management guidance capex

Key Risks

El Niño impact on crop patterns

Analyst raised concern; management acknowledged potential delays in sowing but believes diversified portfolio and geography mitigate risk.

medium · analyst_question

Inventory buildup and working capital strain

Inventory increased to ₹113 crore due to higher cotton production; management expects liquidation over 2 years but carries carrying cost risk.

medium · data_observation

Gross margin normalization

Gross margin fell from 63% to 56% due to product mix; management expects it to stabilize around 53-54%, limiting profit growth.

medium · management_commentary

Uzbekistan JV execution risk

First-year revenue of ₹15 crore is small; management declined to give targets, citing need for more field data.

low · analyst_question

Notable Quotes

We have a very well balanced product portfolio and a very well balanced pan of the selling areas.

Dr. Dinda Kurana · Executive Vice President

It is always better to undercommit and overperform. So we are being conservative because we are just getting settled there.

Satish Kagiwal · Managing Director

Our competition is not with the industry now; our competition is in house. We have to eat our own products.

Harish Pande · Sales Lead

Frequently Asked Questions

What was Nath Bio-Genes's revenue in Q4 FY26?

Nath Bio-Genes reported revenue of ₹432 Cr in Q4 FY26, representing a +19% change compared to the same quarter last year.

What guidance did Nath Bio-Genes management give for FY27?

FY27 revenue growth of 15-20%: Management expects top line to grow 15-20% in FY27, driven by continued momentum in cotton, paddy, and maize. EBITDA and PAT margins to trend slightly upward: Management guided for EBITDA and PAT margins to maintain a slightly upward trend, with PAT margin expected to improve by 1-1.5% over FY26 levels. Minimal capex; focus on rental infrastructure: No major capex planned for processing or storage; company prefers renting to avoid underutilization.

What are the key risks for Nath Bio-Genes in FY27?

Key risks include El Niño impact on crop patterns — Analyst raised concern; management acknowledged potential delays in sowing but believes diversified portfolio and geography mitigate risk.; Inventory buildup and working capital strain — Inventory increased to ₹113 crore due to higher cotton production; management expects liquidation over 2 years but carries carrying cost risk.; Gross margin normalization — Gross margin fell from 63% to 56% due to product mix; management expects it to stabilize around 53-54%, limiting profit growth.; Uzbekistan JV execution risk — First-year revenue of ₹15 crore is small; management declined to give targets, citing need for more field data..

Did Nath Bio-Genes meet its previous quarter's guidance?

Scorecard data is being built as historical quarters are processed.

Where can I read the full Nath Bio-Genes Q4 FY26 concall transcript?

The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.